Maculopathy as a Complication of Blood–Brain Barrier Disruption in Patients with Central Nervous System Lymphoma  

Oleh:

Galor, Anat ; Ference, Sandra J. ; Singh, Arun D. ; Lee, Michael S. ; Stevens, Glen H.J. ; Perez, Victor L. ; Peereboom, David M.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: American Journal of Ophthalmology (keterangan: ada di ClinicalKey) vol. 144 no. 01 (Jul. 2007), page 45.

Ketersediaan

Perpustakaan FK Nomor Panggil: A12.K.2007.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Purpose To report on the development of visually significant maculopathy associated with blood–brain barrier disruption (BBBD) therapy for the treatment of central nervous system (CNS) lymphoma. Design Retrospective case series. Methods Chart review of 20 patients undergoing BBBD therapy for treatment of CNS lymphoma at the Cleveland Clinic. Patients with documented maculopathy were included in analysis. Results Seven (54%) of 13 patients were identified with new macular retinal pigment epithelium (RPE) changes after BBBD treatment. The RPE changes consisted of fine clumps of hyperpigmentation in the foveal region associated with variable degrees of RPE loss. These changes were bilateral but often asymmetric. Two patients had decreased visual acuity resulting from maculopathy. One patient had documented progression of maculopathy after completion of treatment. Conclusions Maculopathy is a frequent finding after BBBD therapy for CNS lymphoma.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali